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Abstract
Background: MicroRNAs (miRNAs) are small non-coding RNA molecules that repress the translation of messenger
RNAs (mRNAs) or degrade mRNAs. These functions of miRNAs allow them to control key cellular processes such as
development, differentiation and apoptosis, and they have also been implicated in several cancers such as
leukaemia, lung, pancreatic and ovarian cancer (OC). Unfortunately, the specific machinery of miRNA regulation,
involving transcription factors (TFs) and transcription co-factors (TcoFs), is not well understood. In the present study
we focus on computationally deciphering the underlying network of miRNAs, their targets, and their control
mechanisms that have an influence on OC development.
Results: We analysed experimentally verified data from multiple sources that describe miRNA influence on
diseases, miRNA targeting of mRNAs, and on protein-protein interactions, and combined this data with ab initio
transcription factor binding site predictions within miRNA promoter regions. From these analyses, we derived a
network that describes the influence of miRNAs and their regulation in human OC. We developed a methodology
to analyse the network in order to find the nodes that have the largest potential of influencing the network’s
behaviour (network hubs). We further show the potentially most influential miRNAs, TFs and TcoFs, showing
subnetworks illustrating the involved mechanisms as well as regulatory miRNA network motifs in OC. We find an
enrichment of miRNA targeted OC genes in the highly relevant pathways cell cycle regulation and apoptosis.
Conclusions: We combined several sources of interaction and association data to analyse and place miRNAs
within regulatory pathways that influence human OC. These results represent the first comprehensive miRNA
regulatory network analysis for human OC. This suggests that miRNAs and their regulation may play a major role in
OC and that further directed research in this area is of utmost importance to enhance our understanding of the
molecular mechanisms underlying human cancer development and OC in particular.
Background
MicroRNAs (miRNAs) are short (~22 nucleotides) non-
coding RNA molecules, which influence gene expression
mainly through degradation of coding mRNA [1,2]. Simi-
lar to protein coding genes, miRNA genes (pri-miRNAs)
thus far identified are predominantly transcribed by RNA
polymerase II [3,4]. New evidence, however, also indi-
cates the involvement of RNA polymerase III for certain
miRNAs [5,6]. These findings suggest that pri-miRNAs
are regulated on the transcriptional level in a similar
fashion as protein coding genes. Following transcription,
pri-miRNAs are cleaved through the microprocessor
complex Drosha and DGCR8 to generate 60~70nt pre-
miRNAs [7,8]. Exportin-5 and its co-factor RanGTP then
export the pre-miRNAs into the cytoplasm [9], where
they are cleaved by Dicer,a nR N a s eI I Ie n d o n u c l e a s e ,t o
yield the mature miRNAs [2,10].
A wide range of mRNAs are targeted by miRNAs.
Numerous databases [11-15], such as the TarBase database
[16] and miRTarBase [17], hold experimentally validated or
computationally predicted miRNA targets. Consequently,
recent experimental and computational studies focus on
the regulatory regions or transcription start sites (TSSs) of
miRNA genes [18-22], their associated transcription factors
(TFs) [23-25], and their effects on miRNA transcription
[23]. Nevertheless, the signals and mechanisms that govern
miRNA transcriptional regulation remain unclear.
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knowledge that a multitude of miRNAs are implicated in a
variety of human diseases [26-28], including several
human cancers [29,30]. Recent studies and reviews
focused on miRNA involvement in the progression of the
most serious gynaecological cancer, ovarian cancer (OC),
and it is now commonly accepted that miRNAs play a role
in OC [31-34]. Experimental data shows that several miR-
NAs exhibit altered expression levels in OC cell lines
[35-37]. Nevertheless, knowledge about possible miRNA
regulatory roles within OC initiation and progression is
incomplete. The transcriptional regulation of the pri-miR-
NAs involved in OC is an important process which, if
understood, could positively impact current treatments
and survival rates of patients with OC.
In the present study, we investigated the underlying net-
work of miRNAs, their targets, and their control mechan-
isms that are associated with OC development. Changes in
miRNA networks between cancerous and healthy tissue
have recently been illuminated [38]. Here we concentrate
on miRNAs and their regulation in OC. We considered all
human miRNAs that are listed in miRBase [15]. For this
set of miRNAs, we extracted experimentally verified tar-
gets from TarBase [16] and miRTarBase [17] and selected
those that have been associated with OC in accordance
with the Dragon Database for Exploration of Ovarian
Cancer Genes (DDOC, [39]). In addition, we mapped tran-
scription factor binding sites (TFBSs) onto extracted pro-
moter regions of the human miRNAs from miRBase to
establish a link between TFs and miRNAs. We considered
two different sizes of promoter regions, 1000nt and
5000nt upstream of the miRNA gene body. In addition,
we incorporated human curated protein-protein interac-
tion (PPI) data from several interaction databases [40-44]
to identify other proteins that may partake indirectly in
the regulation of the miRNAs and to establish links
between all participating proteins in the network.
From these considerations, we derived two large net-
works (one for each considered promoter size) of interact-
ing biological entities (nodes) that are centred on the
m i R N A sa n dt h a ti m p a c tO C .W ec o m b i n e dm i R N A s ,
their downstream targets, and their upstream regulatory
proteins in these networks in order to place these entities
in the context of OC. Subsequently, we devised a metho-
dology to assign a rank to each node according to its
potential for influencing the network’s behaviour. This
rank is based on the number of potential interaction part-
ners that a network node might have as well as the type of
interaction a node engages in. Finally we identified regula-
tory network motifs in the networks. We defined regula-
tory network motifs to be the smallest possible group of
nodes in the network that form a closed circle of interac-
tions with each other. We propose that these network
motifs are integral constituent parts of the network and
the main stepping-stones that can be used to further an
understanding of the networks behaviour, as well as
potential targets for possible attempts to interfere with the
network’s behaviour.
The results of this network analysis show that miR-
NAs and their regulation play an important role within
OC and further in-depth research in this direction may
be rewarding.
Results and discussion
MicroRNAs and their targets involved in OC
The focus of our study is to contribute to the current
knowledge of human miRNA involvement in OC. As a
starting point we used all human miRNAs that are listed
in miRBase [15]. For these we extracted all experimen-
tally confirmed miRNA targets from TarBase [16] and
miRTarBase [17] and subsequently restricted our analysis
to those miRNAs that have an experimentally confirmed
target that is involved in the progression of OC according
to the DDOC database [39]. In total we extracted 162
miRNAs targeting 131 different human proteins. DDOC
lists a total of 379 genes that are relevant for the progres-
sion of OC. This means that more than one third of the
OC genes indentified so far are experimentally confirmed
targets of miRNAs. TarBase and miRTarBase together
list no more than 1800 human genes as confirmed targets
o fm i R N A s .T h i sm e a n st h a tm i R N At a r g e t sa r eo v e r r e -
presented among OC genes with regard to all human
genes. While an explanation for this observation remains
elusive, it merits a closer examination of the role of miR-
NAs and their regulation in OC.
Research by Laios et al. [45] suggests that various miR-
NAs are involved in different stages of cancer progression.
Among the OC-relevant proteins that are experimentally
proven to be targeted by these miRNAs are several pro-
teins that are key members of important cancer pathways.
Two examples are that miR-214 induces cell survival and
cisplatin resistance through targeting the 3’-untranslated
region (UTR) of PTEN, which leads to down-regulation of
PTEN and the activation of the Akt pathway [37]. PTEN is
also targeted by 13 other miRNAs. Furthermore, miR-15b
and miR-16 inhibit BCL2 expression thereby initiating
cleavage of pro-caspase 9 and PARP and consequently
leading to apoptosis [46]. BCL2 is targeted by a total of 23
miRNAs.
MicroRNAs and their regulatory proteins
To increase our understanding of how the 162 miRNAs
identified above are regulated on the transcriptional level,
we extracted the promoter region sequences of the
miRNA genes that correspond to the 162 miRNAs identi-
fied above from the UCSC database [47]. Two different
promoter lengths of 1000nt and 5000nt upstream of the
reported miRNA gene were extracted thereby ensuring
Schmeier et al. BMC Systems Biology 2011, 5:183
http://www.biomedcentral.com/1752-0509/5/183
Page 2 of 9that one component of our analysis focuses on the tran-
scriptional elements in the core promoter while the other
considers a more comprehensive set of cis-regulatory ele-
ments operating at greater distance. Differences in the
resulting networks will aid in highlighting the interactions
of regulatory proteins with regulatory motifs that are pri-
marily located in the core promoter as well as regulatory
processes that include more distally located regulatory
sequence motifs. To do this, we mapped BIOBASE
TRANSFAC binding site motifs to the promoter regions
[48] and linked TFs to the mapped TFBSs (see Methods).
We additionally extracted high-confidence transcription
co-factors (TcoFs) that interact with these TFs from
TcoF-DB [49]. We found that 237 TFs and 140 high-confi-
d e n c eT c o F sm a yb ei n v o l v e di nt h ec o r er e g u l a t i o n
(1000nt upstream) of the 162 OC-associated miRNAs.
When examining the larger and potentially more compre-
hensive set of TFBS (5000nt upstream of the miRNA
genes), 244 TFs were predicted to bind to the extended
promoter regions of OC-associated miRNAs. The seven
additionally considered TFs (GATA6, LHX3, MTF1,
NFIL3, NKX31, ZBTB6, ZN350) only have predicted bind-
ing sites that are more distally located from the TSS and
do not interact with any new high-confidence TcoFs.
Network construction
To generate a network, we extracted from PPI data (see
Methods) all interactions for the targets of all 162 OC-
associated miRNAs, relevant TFs, and TcoFs. After we
combined all the interactions we derived two networks of
interest, one for core promoter regulatory elements
(NW1000) and one for the more comprehensive set of
regulatory elements (NW5000). Table 1 shows the num-
bers of various types of nodes and numbers of interactions
(edges) in the two networks. The complete networks can
be found in the Additional Files 1 and 2. Including PPIs,
transcriptional regulation and miRNA targeting the role of
miRNAs in OC is seen as a complex and highly intercon-
nected network.
Network hubs
To identify those components of the networks that have
the most potential to influence to networks’ overall beha-
viour, we implemented an edge-based ranking system.
Each node is ranked according to a score based on its out-
going edges of the first and second degree (see Methods).
However, there are three different types of edges within
the network, two directed edge types, namely miRNA to
target association, and TF to miRNA association, and
an undirected edge of the type PPI. The latter is assumed
to have the least influence on the information flow within
the network. We assume that the most important edge in
the network et is the interface between a miRNA and its
target, because this is a directed edge that has been
experimentally proven. The second most important edge
er is an association between a TF and a miRNA, even
though only predicted, has a direction. The least important
edge ei is the undirected interaction between two proteins.
This means that each node in the network is ranked
based on the number of potential binding partners as
well as on the type of molecular interaction that it
engages in. Our networks thus constitute a model that
attempts to describe mechanisms in the living cell in the
form of a weighted directed graph. Other aspects of a
living cell, such as expression levels of the genes
involved or the current developmental stage of the cell,
are not part of our model.
Applying our weighting algorithm (see Methods) to the
two networks NW1000 and NW5000 generated a ranking
for each node. The complete node ranking for all nodes in
NW1000 and NW5000 can be found in the Additional
Files 3 and 4. Here we highlight nodes that were ranked
high in both networks. We interpret these nodes as net-
work hubs, potentially having the greatest influence on the
regulation of miRNAs involved in OC.
It is known that elements located far upstream from a
gene can contribute to its regulation [50,51]. However,
when sizing a gene’s upstream region to study its promo-
ter region one has to more or less arbitrarily set a length
limit. Any sequence length chosen is always a trade-off
between excluding elements further upstream that might
be relevant (shorter length) and including them alongside
irrelevant DNA in the analysis introducing noise (longer
length). While aware of these unavoidable shortcomings,
we included two lengths that are frequently chosen as a
compromise.
TFs that are ranked more highly in NW1000 can be
understood to have a higher concentration of binding
sites close to the start of the miRNA genes, while those
that are ranked higher in NW5000 can be interpreted as
h a v i n gat e n d e n c yt ob i n dm o r ed i s t a l l yf r o mt h eg e n e
Table 1 Number of nodes in the networks of OC-
associated elements NW1000 and NW5000
NW1000 NW5000
miRNAs 162 162
miRNA targets (OC cancer genes) 131 131
Transcription factors 237 244
Transcription co-factors 140 140
Edges miRNA® target 434 434
Edges TF ® miRNA 5327 14720
Protein-protein-interactions 4382 4409
Total edges 10143 19563
Total nodes 651 658
The table shows the number of different nodes in the constructed networks.
NW1000 concentrates on regulatory elements in the core promoter while
NW5000 attempts to also include more distally located regulatory elements.
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set of those appearing in NW5000, but the TFs that are
exclusively in NW5000 can be understood to bind to
more remote binding sites. Seven such TFs were identi-
fied (see above).
There is an overlap of six TFs between the nodes
ranked 1
st to 10
th in both networks (BRCA1, SP1, ESR1,
SMAD3, PO2F1, TFE2) and therefore we regard these six
TFs as the essential regulatory elements for miRNA regu-
lation in human OC. Together they are predicted to reg-
ulate 148 out of 162 miRNAs in NW1000, which in turn
target 130 out of 131 experimentally validated miRNA
target proteins. In NW5000, these six TFs participate in
the regulation of all 162 OC relevant miRNAs. This
means that when an upstream regulatory region of
5000nt is considered, these six TFs are predicted to parti-
cipate in the regulation of all OC relevant miRNA genes
and with that have a potential influence on the expres-
sion levels of all OC relevant genes whose mRNAs are
targeted by a miRNA. To the best of our knowledge,
BRCA1, SP1, TFE2, PO2F1 and ESR1 have not been
experimentally validated as TFs of the identified OC rele-
vant miRNAs. It has been demonstrated that ESR1
mediated a decrease in hsa-mir-21 expression correlated
with increased protein expression of endogenous hsa-
mir-21 t a r g e t ss u c ha sP D C D 4 ,P T E N ,a n dB C L 2[ 5 2 ] .I t
has however not been validated that ESR1 mediated this
process as a TF of hsa-mir-21 and no binding site for
ESR1 is predicted in the hsa-mir-21 promoter region
using our method. SMAD3 has been shown to bind and
transcribe the hsa-mir-24 promoter during myoblast dif-
ferentiation [53]. Also, SMAD3 has been implicated in
other diseases by acting as a TF for other miRNAs, for
example: SMAD3 drives hsa-mir-192 expression thereby
mediating renal fibrosis [54] and SMAD3 has been
shown to bind the let-7d promoter thereby promoting
idiopathic pulmonary fibrosis [55].
The highest ranking miRNAs according to our algo-
rithm are hsa-mir-20a, hsa-mir-24-2, hsa-mir-34a, hsa-
mir-21, hsa-mir-17 and hsa-mir-155. This is the first time
that hsa-mir-155 has been linked to the progression of
OC. However, recent research is focused on designing
hsa-mir-155 based therapies as it has been demonstrated
that a moderate increase in hsa-mir-155 levels is observed
in many types of malignancies, and transgenic over-
expression of the miRNA in mice results in cancer, whilst
high levels of hsa-mir-155 expressed during immune
response and hematopoietic lineage differentiation does
not harm the organism [56]. It has recently been shown
that hsa-miR-20a is differentially expressed in female
oocytes [57]. In our networks hsa-mir-20a targets a total
of nine genes that are implicated in the progression of
OC. miR-24 has been found to regulate apoptosis in can-
cer cells and has already been suggested as a drug target
for cancer therapy [58]. For graphical illustration, Figure 1
shows a large, highly connected subnetwork of NW1000
illuminating the interactions of six highly relevant TFs
with six highly ranked miRNAs and their 38 OC relevant
Figure 1 Core network. Large, highly connected subnetwork of NW1000 illuminating the interactions of six highly relevant TFs with six highly
ranked miRNAs and their 38 OC relevant targets. For simplicity the TcoFs that interact with the TFs shown are omitted. The TFs BRCA1, SP1,
ESR1, SMAD3, PO2F1 and TFE2 are ranked very high by our algorithm in both networks NW1000 and NW5000 and can be considered network
hubs for miRNA regulation in human OC.
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shown are omitted.
Among the TcoFs in the networks EP300, RB, UBC9,
HDAC1, MED1, CTNB1, HDAC2, PML and NCOA6 are
ranked high and therefore have a high potential of being
more influential with regard to the networks’ overall beha-
viour than others. These nine TcoFs appear in the list of
best-ranked TcoFs of both networks NW1000 and
NW5000. The human protein EP300 is the highest ranked
TcoF in both networks, NW1000 and NW5000. It inter-
acts with 51 TFs who in turn regulate all but five (all miR-
NAs in NW5000) OC-relevant miRNAs in NW1000.
Figure 2 shows a heatmap illustrating a sub-network of
NW1000 concentrating on the TF BRCA1. This node can
be regarded as the most significant node for OC relevant
miRNA regulation. It is ranked 1
st in both networks
NW1000 and NW5000. This TF regulates 50 miRNAs in
NW1000 (124 in NW5000), which target 66 (115 in
NW5000) proteins involved in OC. The left hand side of
Figure 2 shows all miRNAs that BRCA1 is predicted to
regulate. Across the top all genes are listed that are
reported to be targeted by those miRNAs. The hierarchical
clustering shown here groups miRNAs and proteins
together that display a similar behaviour. The Cyclin-
dependent kinase inhibitor 1 (CDN1A) for example is tar-
geted by 13 different miRNAs.
MicroRNA regulatory network motifs
To better illustrate the cooperation of various nodes in the
network we endeavoured to identify network motifs
shared by both NW1000 and NW5000 networks. We thus
searched for loop-like structures that potentially can be
self-promoting, thus contributing to changed expression
levels of genes and miRNAs during OC progression. Initi-
ally we found five miRNAs in NW1000 (22 in NW5000)
that target one of their own predicted TFs.
Figure 2 Heatmap of a sub-network for significant TF BRCA1. BRCA1 can be regarded as the most significant node for OC relevant miRNA
regulation. It is ranked 1
st in both networks NW1000 and NW5000. This TF regulates 50 miRNAs in NW1000, which target 66 proteins involved in
OC. The vertically arranged miRNAs are all miRNAs that are predicted to be regulated by BRCA1. The horizontally arranged genes are those that
are targeted by the miRNA. BRCA1 is itself targeted by hsa-mir-24-2.
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feature one miRNA and two proteins. In this structure,
one of the proteins acts as a TF by regulating the miRNA,
which in turn targets the other protein. The latter either
simply interacts with the TF or serves as a TcoF for the
regulation of the miRNA. This protein will also be asso-
ciated with OC according to DDOC [39]. Depending on
the observed expression levels of the miRNA in OC, the
levels of the protein target would increase or decrease and
depending on the type of interaction between the two pro-
teins and depending on the type of TF (activator or repres-
sor), this type of loop structure would either be self-
propagating (positive feedback loop) or self-cancelling
(negative feedback loop). Figure 3 summarises the struc-
ture under consideration. NW1000 possesses 232 different
loops of this type, while NW5000 possesses 752 different
loops. The full list of loop structures can be found in the
Additional Files 5 and 6. In NW1000 (NW5000), a total of
67 (98) TFs, 80 (122) miRNAs and 46 (60) genes relevant
for OC progression are involved in these feedback loops.
One interesting protein is the known proto-oncogene
MYC that is found up-regulated in many cancers [59]. It
has recently been suggested that miRNAs that are regu-
lated by MYC should be targeted as a possible therapeutic
strategy [60]. In our network (NW1000) MYC is targeted
by 14 different miRNAs and is predicted to regulate 43
miRNAs. According to our analysis MYC is targeted by
three miRNAs, which are also predicted to be regulated by
MYC. In addition MYC is part of 33 feedback loops. Out
of the 46 OC relevant gene targets that are involved in
feedback loop structures, a significant majority (31 genes)
are involved in the cell cycle regulation pathway. This
pathway is highly relevant for cancer development. While
in general the enrichment of genes relevant to OC in the
cell cycle pathway is quite high (125 out of 379 genes are
involved), the enrichment among genes targeted by miR-
NAs and part of feedback loops is significantly higher.
This means that the expression levels of miRNAs in OC
could have a significant impact on the cell cycle. For
example, the TP53 protein acts as a cell cycle inhibitor.
This protein is targeted by six miRNA and is involved in
17 feedback loops of the type described above. Another
protein that is involved in the cell cycle regulation pathway
is BRCA1 [61]. This protein is involved in 37 possible
feedback loops either as a predicted regulator of miRNAs
or as a confirmed miRNA target. For other types of cancer
it has been shown that changed miRNA expression levels
have the potential to affect relevant pathways and to influ-
ence disease development [62]. Our analysis shows that
miRNAs and their expression potentially play a major role
in OC progression through influencing the cell cycle path-
way. Another pathway that is highly relevant for the pro-
g r e s s i o no fe v e r yc a n c e ri sa p o p t o s i s .W ef i n df i v eO C
relevant genes to be involved in this pathway that are also
targeted by miRNAs and part of regulatory feedback
loops. This points to another potential mechanism, by
which miRNAs and their regulation can possibly affect
OC development and progression.
Conclusions
We have established two networks of miRNA in human
OC, one network that investigates core promoter
Figure 3 Loop structure regulatory network motif. Three-element regulatory loop-structure motif, which features one miRNA and two
proteins. In this structure, one of the proteins would act as a TF by regulating the miRNA, which in turn would target the other protein. The
latter would either simply interact with the TF or serve as a TcoF for the regulation of the miRNA. This protein would also be associated with OC
according to DDOC.
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set of cis-regulatory elements of miRNA regulation. An
examination of these networks with a ranking algorithm
and a search for loop-structured network motifs reveals
some key players in the regulation of miRNA in human
OC. Key miRNAs in the progression of OC appear to be
hsa-mir-20a, hsa-mir-24-2, hsa-mir-34a, hsa-mir-21, hsa-
mir-17 and hsa-mir-hsa-mir-155 while key TFs are
B R C A 1 ,S P 1 ,E S R 1 ,S M A D 3 ,P O 2 F 1a n dT F E 2a m o n g
others.
Methods
miRNAs
We considered all human miRNAs that are listed in
m i R B a s e[ 1 5 ]a n dh a v eac o n f i r m e dt a r g e ti nD D O C
[39].
MicroRNA targets
We extracted targets for miRNAs from the databases for
experimentally verified miRNA targets TarBase [16] and
miRTarBase [17]. We only used targets of miRNAs that
appeared in DDOC [39].
Protein-protein interactions
Human PPI were extracted from the following five data-
bases: IntAct [40], BioGRID [41], HPRD [42], Reactome
[43], and MINT [44].
TFs and TcoFs for miRNAs
Proximal promoter sequences (1000bp upstream) and
more comprehensive promoter sequences (5000bp
upstream) were downloaded from the UCSC Genome
browser [47] for the miRNAs. We used binding site mod-
els from Biobase Knowledge Library (BKL) [48] to map
mammalian TFBSs to the promoter sequences. We only
used those TFBSs that are mapped with a core- and
matrix score of greater than or equal to 0.9. TFs that were
used to create the binding motifs were associated to the
TFBS and thus the link TF® miRNA was created. TcoFs
are proteins that interact with TFs. Either they are TFs
themselves that do not regulate a miRNA or they are pro-
teins that are not themselves binding to the DNA but are
known to interact with a TF and are annotated as partici-
pating in transcriptional regulation. We extracted TcoFs
from TcoF-DB [49]. Only those TcoFs were extracted that
are characterised as ‘high-confidence’ in TcoF-DB.
Network node ranking
Our network model is represented as a weighted directed
graph [63]. To the best of our knowledge there is no stan-
dard procedure for node ranking in weighted directed
graphs. Here we define our own method for node ranking,
which we believe is appropriate to estimate each node’s
potential influence in the biological networks described in
this article. Our measure for a node in the network shows
certain similarities to the Katz centrality measure [64].
However, Katz centrality is only defined for undirected
graphs. In addition, we only consider the influence of
node n to connected nodes up to the second degree,
whereas Katz centrality has no such restriction.
Thus, each node n in the network is ranked according
to its first-degree edges en1 (weighted out-degree, sum
of weights for directed edges from the considered node)
and second-degree edges en2 (weighted out-degree, sum
of weights for directed edges from the first degree nodes
with respect to n). The score Sn for a node n is specified
as:
Sn =

en1 + w ∗

en2,
where w is a weighting factor for the second-degree
edges en2 that should have less influence on the score
then first-degree edges en1.
There are three different types of edges in the network
that are differently weighted:
1. miRNA targets protein ® et
2. TF regulates miRNA ® er
3. Protein-protein interaction ® ei
In the network model, we specify that et =1 ,e t >e r >
ei >0 .T h ew e i g h tf o re r is sampled randomly from a
uniform distribution between 0 and 1. The weight ei is
sampled afterwards from a uniform distribution between
er and 0. Thus it is ensured that always et >e r >e i is
true. In addition, we sample the weighting factor w as
well from a uniform distribution between 0 and 1.
With the three random sampled weights we can calcu-
late Sn for each node n and rank each node in the net-
work according to Sn. Finally this procedure is repeated
10, 000 times with different randomly sampled weights.
The final rank for a node n is the average rank over the
10, 000 rankings. This procedure ensures that no fixed
weighting schema is used.
Additional material
Additional file 1: Network file for NW1000. S1_NW1000_network.txt
contains the complete network NW1000.
Additional file 2: Network file for NW5000. S2_NW5000_network.txt
contains the complete network NW5000.
Additional file 3: Node ranking for NW1000.
S3_NW1000_node_ranking.txt contains the complete node ranking for
NW1000.
Additional file 4: Node ranking for NW5000.
S4_NW5000_node_ranking.txt contains the complete node ranking for
NW5000.
Additional file 5: Network motifs for NW1000.
S5_NW1000_network_motifs.txt contains all network motifs found in
NW1000.
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Page 7 of 9Additional file 6: Network motifs for NW5000.
S6_NW5000_network_motifs.txt contains all network motifs found in
NW5000.
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